{
    "clinical_study": {
        "@rank": "116155", 
        "acronym": "ISST-002 EF-UP", 
        "arm_group": {
            "arm_group_label": "No treatment", 
            "description": "All patients that participated to the therapeutic phase II trial of the Tat vaccine \"ISS T-002\" and that received at least 3 immunizations and reached 48-weeks of follow-up."
        }, 
        "biospec_descr": {
            "textblock": "blood samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "An observational study to prospectively follow-up the patients enrolled in the ISS T-002\n      clinical trial up to 132 weeks. The primary endpoint of this study is to evaluate the\n      persistence, in term of frequency, magnitude and quality, of the anti-Tat humoral and\n      cellular immune response in the HIV-1 infected individuals who participated to the ISS T-002\n      and who have received at least 3 immunizations. The secondary endpoint is to define and\n      validate novel laboratory tests for future efficacy clinical trials."
        }, 
        "brief_title": "Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002", 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previous participation in the ISS T-002 trial, having received at least 3\n             immunizations;\n\n          -  A follow-up of at least 48 weeks during the ISS T-002 study;\n\n          -  Availability to participate in the extended follow-up study;\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  The absence of any of the above criteria will exclude the subjects from the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HAART-treated patients who participated to the therapeutic phase II trial of the Tat\n        vaccine \"ISS T-002\" and received at least 3 immunizations and reached 48-weeks of\n        follow-up."
            }
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118168", 
            "org_study_id": "ISS T-002 EF-UP"
        }, 
        "intervention": {
            "arm_group_label": "No treatment", 
            "description": "No intervention is forseen in this Observational Study", 
            "intervention_name": "No intervention", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "HAART", 
            "Tat Protein"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "url": "http://www.iss.it/aids/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB", 
                        "zip": "20052"
                    }, 
                    "name": "Divisione di Malattie Infettive Azienda Ospedaliera S. Gerardo"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "gioacchino.angarano@uniba.it", 
                    "last_name": "Gioacchino Angarano, MD", 
                    "phone": "+ 39 080 5593", 
                    "phone_ext": "120"
                }, 
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "zip": "70124"
                    }, 
                    "name": "Divisione Malattie Infettive - AO Ospedale Policlinico Consorziale"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ferrara", 
                        "country": "Italy", 
                        "zip": "44124"
                    }, 
                    "name": "Ambulatorio Malattie Infettive - AO Universitaria"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "francesco.mazzotta@asf.toscana.it", 
                    "last_name": "Francesco Mazzotta, MD", 
                    "phone": "+ 39 055 2496", 
                    "phone_ext": "233"
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "zip": "50012"
                    }, 
                    "name": "Unit\u00e0 Operativa di Malattie Infettive - Ospedale S.M. Annunziata"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lazzarin.adriano@hsr.it", 
                    "last_name": "Adriano Lazzarin, MD", 
                    "phone": "+39 02-26437", 
                    "phone_ext": "939"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20124"
                    }, 
                    "name": "U. O. di Malattie Infettive Centro di Ricerca e Cura Patologie HIV correlate - Ospedale San Raffaele"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "massimo.galli@unimi.it", 
                    "last_name": "Massimo Galli, MD", 
                    "phone": "+39 02 39042", 
                    "phone_ext": "451"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20152"
                    }, 
                    "name": "Istituto di Malattie Infettive e Tropicali - AO Luigi Sacco"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "crimus@unimore.it", 
                    "last_name": "Cristina Mussini, MD", 
                    "phone": "+39 059 4222", 
                    "phone_ext": "827"
                }, 
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "zip": "41100"
                    }, 
                    "name": "Divisione di Malattie Infettive - AO Universitaria Policlinico"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "a.latini@ifo.it", 
                    "last_name": "Alessandra Latini, MD", 
                    "phone": "+39 06-5266", 
                    "phone_ext": "2804"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00144"
                    }, 
                    "name": "U.O.C. Dermatologia Infettiva ed Allergologica - IFO San Gallicano"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "OBSERVATIONAL STUDY FOR THE EXTENDED FOLLOW-UP OF THE PATIENTS ENROLLED IN THE PHASE II THERAPEUTIC CLINICAL TRIAL ISS T-002", 
        "overall_contact": {
            "email": "barbara.ensoli@iss.it", 
            "last_name": "Barbara Ensoli, MD, PHD", 
            "phone": "+39 06 4990", 
            "phone_ext": "3209"
        }, 
        "overall_official": {
            "affiliation": "Istituto Superiore di Sanit\u00e0", 
            "last_name": "Barbara Ensoli, MD, PHD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: AIFA", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is to evaluate the persistence, in term of frequency, magnitude, and quality of the anti-Tat humoral immune response in HAART-treated patients previously immunize with Tat in the ISS T-002 phase II clinical trial.", 
            "measure": "anti-Tat humoral immune response", 
            "safety_issue": "No", 
            "time_frame": "Every 3 months, up to 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118168"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istituto Superiore di Sanit\u00e0", 
            "investigator_full_name": "Barbara Ensoli, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary endpoint of the study is to identify and validate immunological  testing for future efficacy vaccine clinical trials, as follows: Lymphoproliferative response to Tat/in vitro anti-Tat \u03b3IFN, IL4 and IL2 production; In vitro neutralization of Tat activity (Tat/Env uptake); Lymphocyte subsets; Anti-Tat IgG subclasses; Epitope mapping of anti-Tat IgM and IgG; Anti-HIV regulatory and structural proteins antibodies; ADCC; Neutralization of Tat activity by rescue assay; Neutralization of primary HIV isolates; Anti-CCR5 and Anti-CD4  antibodies; Lymphoproliferative response to Env, mitogens and recall antigens In vitro \u03b3IFN, IL4 and IL2 production in response to Tat (ICS) and to Env (ICS/Elispot); B cells phenotype; Characterization of Treg cells; PBMC ICS for granzyme, perforin, cytokines and chemokines; Th1 and Th2 cytokines and chemokines; Lymphocytes spontaneous cell death; Bcell cloning; Characterization of clono-specific antibodies; Serum/plasma determination of sCD4", 
                "measure": "Testing of the additional Immunological parameters detailed below as a second line testing", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 2.5 years"
            }, 
            {
                "description": "The secondary endpoint of the study is to identify and validate virological testing for future efficacy vaccine clinical trials, as follows: HIV-1 plasma viremia (viral RNA copies) HIV-1 sequencing and virus phylogenetic analysis Genotypic resistance Viral tropism Anti-HBV antibodies HBV antigens (HbsAg, HbeAg) Anti-HCV antibodies and plasma viremia HHV-8 antibodies and plasma viremia HIV-1 Proviral DNA copies", 
                "measure": "Testing of virological parameters detalied below, as a second line testing", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 2.5 years"
            }
        ], 
        "source": "Istituto Superiore di Sanit\u00e0", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barbara Ensoli, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}